{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:52:03Z","timestamp":1787701923010,"version":"build-2784847793"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["11669"],"award-info":[{"award-number":["11669"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001755","name":"Mesothelioma Applied Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001755","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13045-016-0387-6","type":"journal-article","created":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T04:16:04Z","timestamp":1484712964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism"],"prefix":"10.1186","volume":"10","author":[{"given":"Rihan","family":"El Bezawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelandrea","family":"De Cesare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Pennati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Deraco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gandellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Zuco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Zaffaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,18]]},"reference":[{"key":"387_CR1","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1245\/s10434-012-2845-x","volume":"20","author":"M Deraco","year":"2013","unstructured":"Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20:1093\u2013100.","journal-title":"Ann Surg Oncol"},{"key":"387_CR2","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1016\/j.ejca.2013.05.027","volume":"49","author":"D Baratti","year":"2013","unstructured":"Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer. 2013;49:3140\u20138.","journal-title":"Eur J Cancer"},{"key":"387_CR3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","volume":"136","author":"DP Bartel","year":"2009","unstructured":"Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215\u201333.","journal-title":"Cell"},{"key":"387_CR4","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.molonc.2012.09.006","volume":"6","author":"MD Jansson","year":"2012","unstructured":"Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol. 2012;6:590\u2013610.","journal-title":"Mol Oncol"},{"key":"387_CR5","doi-asserted-by":"crossref","first-page":"e1327","DOI":"10.1038\/cddis.2014.270","volume":"5","author":"XJ Li","year":"2014","unstructured":"Li XJ, Ren ZJ, Tang JH. MicroRNA-34a: a potential therapeutic target in human cancer. Cell Death Dis. 2014;5:e1327.","journal-title":"Cell Death Dis"},{"key":"387_CR6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12885-016-2135-2","volume":"16","author":"G Schmid","year":"2016","unstructured":"Schmid G, Notaro S, Reimer D, Abdel-Azim S, Duggan-Peer M, Holly J, et al. Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer. BMC Cancer. 2016;16:102.","journal-title":"BMC Cancer"},{"key":"387_CR7","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1158\/0008-5472.CAN-12-2230","volume":"72","author":"KO Henrich","year":"2012","unstructured":"Henrich KO, Schwab M, Westermann F. 1p36 tumor suppression\u2014a matter of dosage? Cancer Res. 2012;72:6079\u201388.","journal-title":"Cancer Res"},{"key":"387_CR8","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1038\/mtna.2014.47","volume":"3","author":"G Misso","year":"2014","unstructured":"Misso G, Di Martino MT, De Rosa G, Farooqi AA, Lombardi A, Campani V, et al. Mir-34: a new weapon against cancer? Mol Ther Nucleic Acids. 2014;3:e194.","journal-title":"Mol Ther Nucleic Acids"},{"key":"387_CR9","unstructured":"Mirna Therapeutics, Inc; Cancer Prevention Research Institute of Texas. A multicenter phase I study of MRX34, microRNA miR-RX34 liposomal injection. In: ClinicalTrials.gov [Internet]. Bethesda: National Library of Medicine (US). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01829971 NLM Identifier: NCT01829971. Accessed 20 July 2016."},{"key":"387_CR10","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1016\/j.ejca.2010.06.130","volume":"46","author":"F Perrone","year":"2010","unstructured":"Perrone F, Jocoll\u00e8 G, Pennati M, Deraco M, Baratti D, Brich S, et al. Receptor tyrosine kinases and downstream signaling analysis in diffuse malignant peritoneal mesothelioma. Eur J Cancer. 2010;46:2837\u201348.","journal-title":"Eur J Cancer"},{"key":"387_CR11","doi-asserted-by":"crossref","first-page":"13119","DOI":"10.18632\/oncotarget.3761","volume":"6","author":"M Cesare De","year":"2015","unstructured":"De Cesare M, Cominetti D, Doldi V, Lopergolo A, Deraco M, Gandellini P, et al. Anti-tumor activity of selective inhibitors of XPO1\/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin. Oncotarget. 2015;6:13119\u201332.","journal-title":"Oncotarget"},{"key":"387_CR12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12967-016-0781-4","volume":"14","author":"M Cesare De","year":"2016","unstructured":"De Cesare M, Sfondrini L, Pennati M, De Marco C, Motta V, Tagliabue E, et al. CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts. J Transl Med. 2016;14:25.","journal-title":"J Transl Med"},{"key":"387_CR13","doi-asserted-by":"crossref","first-page":"7223","DOI":"10.1021\/acs.jmedchem.6b00777","volume":"59","author":"V Span\u00f2","year":"2016","unstructured":"Span\u00f2 V, Pennati M, Parrino B, Carbone A, Montalbano A, Cilibrasi V, et al. Preclinical activity of new [1,2]oxazolo[5,4-e]isoindole derivatives in diffuse malignant peritoneal mesothelioma. J Med Chem. 2016;59:7223\u201338.","journal-title":"J Med Chem"},{"key":"387_CR14","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.bcp.2009.09.012","volume":"79","author":"V Zuco","year":"2010","unstructured":"Zuco V, Supino R, Favini E, Tortoreto M, Cincinelli R, Croce AC, et al. Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma. Biochem Pharmacol. 2010;79:535\u201341.","journal-title":"Biochem Pharmacol"},{"key":"387_CR15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canlet.2009.12.001","volume":"292","author":"V Zuco","year":"2010","unstructured":"Zuco V, Benedetti V, Zunino F. ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968. Cancer Lett. 2010;292:186\u201396.","journal-title":"Cancer Lett"},{"key":"387_CR16","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1078-0432.CCR-13-1684","volume":"20","author":"M Cesare De","year":"2014","unstructured":"De Cesare M, Lauricella C, Veronese SM, Cominetti D, Pisano C, Zunino F, et al. Synergistic antitumor activity of cetuximab and namitecan in human squamous cell carcinoma models relies on cooperative inhibition of EGFR expression and depends on high EGFR gene copy number. Clin Cancer Res. 2014;20:995\u20131006.","journal-title":"Clin Cancer Res"},{"key":"387_CR17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and life tables. J R Stat Soc Series B Stat Methodol. 1972;34:187\u2013220.","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"387_CR18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1055-3207(03)00037-1","volume":"12","author":"O Glehen","year":"2003","unstructured":"Glehen O, Gilly FN. Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis and peritoneal mesothelioma. Surg Oncol Clin N Am. 2003;12:649\u201371.","journal-title":"Surg Oncol Clin N Am"},{"key":"387_CR19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/sj.emboj.7600045","volume":"23","author":"H Miyauchi","year":"2004","unstructured":"Miyauchi H, Minamino T, Tateno K, Kunieda T, Toko H, Komuro I. Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53\/p21-dependent pathway. EMBO J. 2004;23:212\u201320.","journal-title":"EMBO J"},{"key":"387_CR20","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/onc.2011.394","volume":"31","author":"MV Astle","year":"2012","unstructured":"Astle MV, Hannan KM, Ng PY, Lee RS, George AJ, Hsu AK, et al. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. Oncogene. 2012;31:1949\u201362.","journal-title":"Oncogene"},{"key":"387_CR21","doi-asserted-by":"crossref","first-page":"872","DOI":"10.18632\/oncotarget.1825","volume":"5","author":"M Agostini","year":"2014","unstructured":"Agostini M, Knight RA. miR-34: from bench to bedside. Oncotarget. 2014;5:872\u201381.","journal-title":"Oncotarget"},{"key":"387_CR22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/cdd.2009.56","volume":"17","author":"H Hermeking","year":"2010","unstructured":"Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010;17:193\u20139.","journal-title":"Cell Death Differ"},{"key":"387_CR23","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fgene.2012.00120","volume":"3","author":"AG Bader","year":"2012","unstructured":"Bader AG. miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet. 2012;3:120.","journal-title":"Front Genet"},{"key":"387_CR24","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1038\/bjc.2014.220","volume":"110","author":"S Zhou","year":"2014","unstructured":"Zhou S, Liu L, Li H, Eilers G, Kuang Y, Shi S, et al. Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma. Br J Cancer. 2014;110:2479\u201388.","journal-title":"Br J Cancer"},{"key":"387_CR25","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1158\/1078-0432.CCR-10-1993","volume":"17","author":"IS Donev","year":"2011","unstructured":"Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, et al. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res. 2011;17:2260\u20139.","journal-title":"Clin Cancer Res"},{"key":"387_CR26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-0609.2009.01387.x","volume":"84","author":"VZM Suzuki","year":"2010","unstructured":"Suzuki VZM, Abe A, Imagama S, Nomura Y, Tanizaki R, Minami Y, et al. BCR-ABL-independent and RAS\/MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4. Eur J Haematol. 2010;84:229\u201338.","journal-title":"Eur J Haematol"},{"key":"387_CR27","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1158\/2159-8290.CD-12-0103","volume":"2","author":"D Ercan","year":"2012","unstructured":"Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov. 2012;2:934\u201347.","journal-title":"Cancer Discov"},{"key":"387_CR28","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/JTO.0b013e318215a07d","volume":"6","author":"M Brevet","year":"2011","unstructured":"Brevet M, Shimizu S, Bott MJ, Shukla N, Zhou Q, Olshen AB, et al. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy. J Thorac Oncol. 2011;6:864\u201374.","journal-title":"J Thorac Oncol"},{"issue":"Suppl 1","key":"387_CR29","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1177\/1758834011422556","volume":"3","author":"SL Organ","year":"2011","unstructured":"Organ SL, Tsao MS. An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 2011;3(Suppl 1):S7\u201319.","journal-title":"Ther Adv Med Oncol"},{"key":"387_CR30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3857\/roj.2015.33.4.328","volume":"33","author":"O Cho","year":"2015","unstructured":"Cho O, Hwang HS, Lee BS, Oh YT, Kim CH, Chun M. Met inactivation by S-allylcysteine suppresses the migration and invasion of nasopharyngeal cancer cells induced by hepatocyte growth factor. Radiat Oncol J. 2015;33:328\u201336.","journal-title":"Radiat Oncol J"},{"key":"387_CR31","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.4161\/15384047.2014.956634","volume":"15","author":"K P\u00e9nzes","year":"2014","unstructured":"P\u00e9nzes K, Baumann C, Szabadkai I, Orfi L, K\u00e9ri G, Ullrich A, et al. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells. Cancer Biol Ther. 2014;15:1571\u201382.","journal-title":"Cancer Biol Ther"},{"key":"387_CR32","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/onc.2012.587","volume":"33","author":"S Ammoun","year":"2014","unstructured":"Ammoun S, Provenzano L, Zhou L, Barczyk M, Evans K, Hilton DA, et al. Axl\/Gas6\/NF\u03baB signalling in schwannoma pathological proliferation, adhesion and survival. Oncogene. 2014;33:336\u201346.","journal-title":"Oncogene"},{"key":"387_CR33","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrc3847","volume":"14","author":"DK Graham","year":"2014","unstructured":"Graham DK, DeRyckere D, Davies KD, Earp HS. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer. 2014;14:769\u201385.","journal-title":"Nat Rev Cancer"},{"key":"387_CR34","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1158\/0008-5472.CAN-06-4416","volume":"67","author":"N Puri","year":"2007","unstructured":"Puri N, Khramtsov A, Ahmed S, Nallasura V, Hetzel JT, Jagadeeswaran R, et al. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 2007;67:3529\u201334.","journal-title":"Cancer Res"},{"key":"387_CR35","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1038\/onc.2009.212","volume":"28","author":"Y Li","year":"2009","unstructured":"Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J, et al. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene. 2009;28:3442\u201355.","journal-title":"Oncogene"},{"key":"387_CR36","doi-asserted-by":"crossref","first-page":"15029","DOI":"10.1074\/jbc.M115.678490","volume":"291","author":"V Stepanova","year":"2016","unstructured":"Stepanova V, Jayaraman PS, Zaitsev SV, Lebedeva T, Bdeir K, Kershaw R, et al. Urokinase-type plasminogen activator (uPA) promotes angiogenesis by attenuating Proline-rich homeodomain protein (PRH) transcription factor activity and de-repressing vascular endothelial growth factor (VEGF) receptor expression. J Biol Chem. 2016;291:15029\u201345.","journal-title":"J Biol Chem"},{"key":"387_CR37","doi-asserted-by":"crossref","first-page":"32360","DOI":"10.1074\/jbc.M110.131045","volume":"285","author":"L Qin","year":"2010","unstructured":"Qin L, Zhang M. Maspin regulates endothelial cell adhesion and migration through an integrin signaling pathway. J Biol Chem. 2010;285:32360\u20139.","journal-title":"J Biol Chem"},{"key":"387_CR38","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/72303","volume":"6","author":"M Zhang","year":"2000","unstructured":"Zhang M, Volpert O, Shi YH, Bouck N. Maspin is an angiogenesis inhibitor. Nat Med. 2000;6:196\u20139.","journal-title":"Nat Med"},{"key":"387_CR39","doi-asserted-by":"crossref","unstructured":"Saito Y, Nakaoka T, Saito H. microRNA-34a as a therapeutic agent against human cancer. J Clin Med. 2015;4:1951\u20139.","DOI":"10.3390\/jcm4111951"},{"key":"387_CR40","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.4161\/cc.7.16.6533","volume":"7","author":"D Lodygin","year":"2008","unstructured":"Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, Knyazev P, Diebold J, Hermeking H. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle. 2008;7:2591\u2013600.","journal-title":"Cell Cycle"},{"key":"387_CR41","doi-asserted-by":"crossref","first-page":"7569","DOI":"10.1158\/0008-5472.CAN-09-0529","volume":"69","author":"Y Li","year":"2009","unstructured":"Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 2009;69:7569\u201376.","journal-title":"Cancer Res"},{"key":"387_CR42","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"36","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;36:6237\u201342.","journal-title":"J Clin Oncol"},{"key":"387_CR43","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13045-016-0323-9","volume":"9","author":"X Wang","year":"2016","unstructured":"Wang X, Wang C, Zhang X, Hua R, Gan L, Huang M, et al. Bmi-1 regulates stem cell-like properties of gastric cancer cells via modulating miRNAs. J Hematol Oncol. 2016;9:90.","journal-title":"J Hematol Oncol"},{"key":"387_CR44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.canlet.2008.09.035","volume":"275","author":"N Li","year":"2009","unstructured":"Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 2009;275:44\u201353.","journal-title":"Cancer Lett"},{"key":"387_CR45","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1476-4598-13-8","volume":"13","author":"H Li","year":"2014","unstructured":"Li H, Yu G, Shi R, Lang B, Chen X, Xia D, et al. Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy. Mol Cancer. 2014;13:8.","journal-title":"Mol Cancer"},{"key":"387_CR46","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bcp.2015.10.015","volume":"98","author":"Y Zhao","year":"2015","unstructured":"Zhao Y, Tu MJ, Yu YF, Wang WP, Chen QX, Qiu JX, et al. Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth. Biochem Pharmacol. 2015;98:602\u201313.","journal-title":"Biochem Pharmacol"},{"key":"387_CR47","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.bbrc.2008.09.086","volume":"377","author":"Y Fujita","year":"2008","unstructured":"Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y, et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun. 2008;377:114\u20139.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-016-0387-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T21:43:37Z","timestamp":1719006217000},"score":1,"resource":{"primary":{"URL":"http:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-016-0387-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,18]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["387"],"URL":"https:\/\/doi.org\/10.1186\/s13045-016-0387-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,18]]},"article-number":"19"}}